Trial Profile
BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms BRCA-P
- 09 Nov 2022 Status changed from not yet recruiting to recruiting.
- 09 Nov 2022 According to ISRCTN: Current Controlled Trials record, recruitment is expected to begin on 20 Nov 2022 and recruitment completion is expected on 7 Nov 2024.
- 09 Nov 2022 Status changed from recruiting to not yet recruiting.